ProText Mobility Inc (TXTM)

[Strukture]

TXTM News update

PLANDAI BIOTECHNOLOGY PROVIDES CLARIFICATION ON RECENT UPDATES RELATING TO THE BUSINESS OF PROTEXT PHARMA

THIS IS ACTUALLY TXTM News!!
https://www.otcmarkets.com/stock/PLPL/news/story?e&id=1062756

Florida, USA -- May 23, 2018 -- InvestorsHub NewsWire -- Protext Pharma, Inc. (PINKSHEETS: TXTM) ("Protext" or "the Company"), a biotech company engaged in the development of pharmaceutical botanical medicines that are formulated with highly-bioavailable plant extracts, today provided the following statement from Plandai Biotechnology (PLPL) in regards to clarifying recent updates.

Callum Cottrell-Duffield, Chief Operating Officer of Plandaí Biotechnology, today released the following statement. "Plandaí routinely releases updates on subsidiary operations. We are aware that Plandaí’s press release from April 25 created some confusion with shareholders. In December 2016, Protext Pharma acquired from Plandai the entity Plandai Biotechnology SA (PTY), which has a license to develop Phytofare® products for pharmaceutical applications including diabetes. In March 2017, Protext acquired from Plandaí the entity Cannabis Biosciences, Inc., which is a Delaware company that has the license to develop pharmacologic applications using cannabis and the Phytofare® extraction platform. Since acquiring these business' from Plandai (PLPL), Protext management has applied for a medical cannabis license from the South African government which upon issuance would allow for the legal cultivation, extraction, testing, and development of a medicinal platform for cannabis extracts.”